Wednesday, 28 Jun 2017

You are here

Upadacitinib Effective in Rheumatoid Arthritis

AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in established RA patients who have failed prior DMARD therapy.

Two doses of upadacitinib (15 mg and 30 mg) were studied against placebo for 12 weeks and shown to produced significantly greater ACR20, ACR50, and  ACR70 scores (64%, 66%, 20%, respectively).

Clinical remission was seen in 31%, 28% and 10%, of those taking 15 mg, 30 mg and placebo (p<0.001). Low disease activity was achieved in 48% of patients on upadacitinib, compared to 17% of patients on placebo).

No new or surprising safety signals were reported.

Updacitinib is being considered for other indications, including psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis.

 

 

 

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Supreme Court Decision Favors Earlier Biosimilar Adoption

On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.

Biosimilar Reports – May 2017

Biosimilars continue to command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. Biosimilar Reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. 

Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis

The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Actemra - First FDA Approved Drug for Giant Cell Arteritis

The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.

Tofacitinib Effective in Ulcerative Colitis

Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).